Signaturefd LLC Sells 1,283 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Signaturefd LLC lowered its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 33.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,571 shares of the biopharmaceutical company’s stock after selling 1,283 shares during the quarter. Signaturefd LLC’s holdings in Royalty Pharma were worth $66,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in RPRX. Swedbank AB increased its holdings in Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock valued at $310,308,000 after buying an additional 1,136,800 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Royalty Pharma by 58.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock worth $84,915,000 after purchasing an additional 1,103,341 shares in the last quarter. Two Sigma Advisers LP raised its holdings in Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after purchasing an additional 936,900 shares during the period. Raymond James Financial Inc. purchased a new position in Royalty Pharma during the fourth quarter valued at $19,990,000. Finally, Point72 Asset Management L.P. bought a new stake in Royalty Pharma during the third quarter valued at about $14,898,000. Institutional investors own 54.35% of the company’s stock.

Analysts Set New Price Targets

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $41.60.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock opened at $33.75 on Tuesday. The company has a market capitalization of $19.46 billion, a price-to-earnings ratio of 23.28, a PEG ratio of 2.31 and a beta of 0.47. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock’s 50-day simple moving average is $32.33 and its 200-day simple moving average is $28.75. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.61%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is presently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.